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Dividing patients into NTproBNP quartiles, %ECW/TBW and 
relative ECW overhydration were significantly greater for the 
highest quartile vs. lowest (40.5 ± 4.1 vs. 39.0 ± 1.1, and 
1.51 ± 1.24 vs. 0.61 ± 0.69 l, respectively, p < 0.001).  Conclu-
sion: In this study, predialysis NTproBNP values were associ-
ated with direct assessments of the extracellular volume ex-
cess measured by MFBIA and systolic arterial blood pressure. 
This suggests that predialysis NTproBNP values can poten-
tially be used to aid clinical assessment of volume status in 
dialysis patients to determine target weight. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Cardiovascular disease remains the most common 
cause of death in haemodialysis patients  [1] . However, 
compared to the general population, haemodialysis pa-
tients have increased arteriosclerosis and left-ventricular 
hypertrophy, rather than atheromatous vascular disease. 
Similarly, haemodialysis patients have an increased prev-
alence of left-ventricular diastolic dysfunction, which 
may develop following recurrent episodes of volume 
overload predialysis  [2] . Reducing the number of epi-
sodes of volume overload by more frequent dialysis was 
recently reported to lead to a reduction in both systolic 
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 Abstract 
 Introduction: Increased natriuretic peptides are associated 
with increased cardiovascular and all-cause mortality for 
haemodialysis (HD) patients. However, debate continues 
whether these biomarkers are increased by extracellular wa-
ter (ECW) excess and can be used to aid clinical assessment 
of volume status and help determine target weight.  Meth-
ods: We measured N terminal probrain natriuretic peptide 
(NT-proBNP) predialysis in 375 stable haemodialysis outpa-
tients with corresponding pre and postdialysis multifre-
quency bioelectrical impedance assessments (MFBIA) of 
(ECW)/total body water (TBW).  Results: Median age 64 (51–
75), 63.9% male, 42.9% diabetic, 43.2% Caucasoid, 14.4% 
with a history of myocardial infarction, 8.4% coronary artery 
bypass surgery, dialysis vintage 28.2 (12.3–55.5) months. Me-
dian predialysis NT-proBNP 283 (123–989) pmol/l, and pre-
dialysis ECW/TBW ratio 0.397 ± 0.029. On multivariate analy-
sis, predialysis log NT-proBNP was associated with predialy-
sis systolic blood pressure (β 0.007, p = 0.000), weight (β 
 − 0.008, p = 0.001), valvular heart disease (β 0.342, p = 0.015, 
ECW/TBW (β 1.3, p = 0.019) and log CRP (β 0.145, p = 0.037). 
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blood pressure and left-ventricular mass  [3] . Natriuretic 
peptides were introduced into routine general medical 
clinical practice as biomarkers to aid the diagnosis of 
heart failure. Previous studies have reported a strong in-
verse association between BNP and survival in dialysis 
patients  [4] . Although BNP is filtered by the glomerulus 
and degraded in the proximal renal tubules, there is sig-
nificant extra renal clearance of natriuretic peptides so 
that many dialysis patients can have normal concentra-
tions  [5] . As such there has been debate in the published 
literature as to whether measurement of natriuretic pep-
tides can add value in aiding clinical judgement of volume 
status in haemo and peritoneal dialysis patients  [6–12] . 
While NT-proBNP is not affected by peritoneal dialysis 
exchanges, NT-proBNP concentrations fall after high-
flux haemodialysis and haemodiafiltration  [13] . We 
therefore elected to determine whether predialysis NT-
proBNP measurements were increased in patients with 
an expanded extracellular water space as measured by 
multifrequency bioelectrical impedance  [13] .
 Methods and Patients 
 375 stable established haemodialysis outpatients, attending 
their routine mid-week haemodialysis session, using either Frese-
nius 4008H/5000H or BBraun Dialogue+ ® dialysis machines with 
integrated blood pressure monitors (Fresenius Bad Homburg, 
Germany and BBraun, Melsungen, Germany), polysulfone dialyz-
ers (Nipro Corporation, Osaka, Japan)  [14] , with ultrapure quality 
dialysis water and anticoagulation with low molecular weight hep-
arin (Tinzaparin, Leo Laboratories, Princes Risborough, UK)  [15] 
were studied. Multifrequency bio-electrical impedance assess-
ments (MF-BIA) were standardized by taking measurements pre 
and 20–30 minutes postdialysis session, using an eight-electrode 
MF-BIA device (Biospace In body 720, Seoul, South Korea)  [16, 
17] . Patients with pacemakers or implantable defibrillators and 
amputees were excluded from study. Relative extracellular water 
volume (ECW) excess termed extracellular water overhydration 
was estimated according to the method recommended by the 
 European Society for Parenteral and Enteral Nutrition (ESPN) 
 [18] .
 Serum biochemistry samples were analysed with a standard 
multi-channel biochemical analyzer (Roche Integra, Roche diag-
nostics, Lewes, UK), using the bromcresol green method for albu-
min determination, NT-proBNP was measured by immunoassay 
(ECLIA Roche Diagnostics, GMBH, Mannhein, Germany), with 
an inter assay coefficient of variation 1.3%.
 Electronic patient medical records were reviewed to obtain rel-
evant clinical information and prescribed medication history.
 Ethical approval was granted by the Royal Free Hospital re-
search and development department as audit and clinical service 
development, and the audit was conducted according to the UK 
National Health Service guidelines on clinical audit and service 
development.
 Statistical Analysis 
 Results are expressed as mean ± standard deviation, or median 
and interquartile range, or percentage. Statistical analysis was by 
Students’ paired  t test for parametric and the Wilcoxon rank sum 
pair test for nonparametric data, with Bonferroni correction for 
multiple analyses where appropriate, and anova with Tukey or 
Dunnett’s post hoc correction (GraphPad Prism version 6.0, 
GraphPad, San Diego, Calif., USA). Simple correlation analysis 
was performed with Pearson’s rank correlation and then multiple 
linear regression analysis using backward step multivariate analy-
sis was used excluding variables that were not significant and did 
not improve the fit of the model, and retaining variables in the 
model where the 95% confidence intervals for the estimate did not 
include zero or there was an improvement in model fit (as demon-
strated by the -2log likelihood), using SPSS version 210 (SPSS, 
Univ Chicago, Ill., USA), which was also used to calculate a re-
ceiver operating characteristic curve (ROC) sensitivity and speci-
ficity analysis. Nonparametric variables were log transformed to 
allow analysis. Statistical significance was taken at or below the 5% 
level.
 Results 
 The median age of the 375 patients was 64 (51–75) 
years, 63.9% male, 42.9% diabetic, 43.2% Caucasoid, 38% 
 African or Afro-Caribbean, 21.6% South Asian, with a 
dialysis vintage of 28.2 (12.3–65.5) months, and postdi-
alysis body mass index of 26.4 ± 6.3 kg/m 2 . Antihyperten-
sive medications were prescribed to 51.1% of the patient 
cohort, with the average number of antihypertensive 
medications prescribed per patient 1 (0–1). The com-
monest antihypertensive medications prescribed were 
beta blockers 33.2%, followed by calcium channel antago-
nists at 12.8 and 10.5% for both angiotensin converting 
enzyme inhibitors and sartanes. 56.2% were prescribed 
aspirin or clopidogrel and 4.8% warfarin. 14.4% had a pri-
or documented myocardial infarction, 8.4% coronary ar-
tery bypass surgery, 10.4% coronary artery stenting, 8.0% 
had heart valve replacement or severe valvular heart dis-
ease, 10.3% peripheral vascular disease, and 12.4% cere-
brovascular disease mean dialysis session time 4 (3.5–4.0) 
hours, urea reduction ratio 74.6 ± 8.3%. Predialysis hae-
moglobin 113.4 ±13.9 g/l, serum albumin 40 (37–42) g/l, 
blood glucose 6.4 (5.5–7.8) mmol/l, C-reactive protein 9.4 
(2–11) mg/l. Pre and postdialysis biochemistries, blood 
pressure and bio-impedance assessments are set out in 
 table 1 .
 NT-proBNP values were not normally distributed 
with the median predialysis NT-proBNP 283 (123–989) 
pmol/l. As such NTproBNP values were log transformed 
and were correlated with markers of volume overload; 
extracellular water to total body water ratio (ECW/TBW) 
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relative extracellular water overhydration, age, sex, weight 
cardiovascular disease and also systolic blood pressure 
(online suppl. table 1; for all online suppl. material, see 
www.karger.com/doi/10.1159/000368376). We then per-
formed a backward multivariate analysis, excluding vari-
ables that were not significant or failed to improve the 
model fit and log predialysis NTproBNP was associated 
with ECW/TBW, valvular heart disease, C-reactive pro-
tein (CRP), systolic blood pressure, and weight ( table 2 ).
 We then divided patients into quartiles of predialysis 
NTproBNP. Those patients in the highest NTproBNP 
had greater systolic blood pressure, both pre and postdi-
alysis ( fig.  1 ). Patients in the lowest NTproBNP were 
heavier, with greater body fat and had higher serum albu-
min and lower CRP concentrations (table 3). Although 
bioimpedance assessments did not show absolute differ-
ences ( table 3 ), both relative extracellular water overhy-
dration and the ratio of extracellular water (ECW) to total 
body water (TBW) were greater in those in the highest 
quartile cohort both pre and postdialysis ( fig. 2 and  3 ).
Table 1.  Pre and postdialysis biochemistries, blood pressure and volume assessments
Predialysis Postdialysis
Serum urea, mmol/l 18.4±5.3 4.9±2.5***
Serum sodium, mmol/l 138.9±3.3 138.8±2.9
Systolic blood pressure, mm Hg 141.5±26.0 129.5±26.0***
Diastolic blood pressure, mm Hg 75.3±16.4 71.2±15.4**
Mean arterial blood pressure, mm Hg 97.0±17.0 90.2±17.6***
Intracellular water (ICW), l 22.7±5.9 21.5±4.1***
Extracellular water (ECW), l 14.9±3.9 13.4±2.8***
% Extracellular water/total body water 39.7±2.9 39.0±1.7***
Weight, kg 73.6±19.0 71.8±19.3***
 Variables expressed as mean ± SD. *** p < 0.001 vs. predialysis.
Table 2.  Multiple regression model for logNTproBNP taken in the predialysis session
variable β coefficient SE t F 95% CL p value
SBP, mm Hg 0.007 0.002 4.16 17.3 0.004 to 0.10 0.000
Weight, kg –0.008 0.002 –3.5 12.24 –0.013 to –0.004 0.001
Valve 0.342 0.14 2.45 5.99 0.066 to 0.613 0.015
%ECW/TBW 0.013 0.03 2.36 5.56 0.005 to 0.056 0.019
log CRP, g/l 0.145 0.069 2.10 4.4 0.009 to 0.281 0.037
 %ECW/TBW = Percentage extracellular weight/total body water ratio; SBP = systolic blood pressure; v = val-
vular heart disease; CRP = C-reactive protein; SE = standard error; CL = confidence limits and adjusted r2 value 
for model 0.38.
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 Fig. 1. Systolic blood pressure (mm Hg) pre dialysis in patients di-
vided into four quartiles according to predialysis NT-proBNP 
pmol/l. Values expressed as mean ± SD.  * *  p < 0.01 and  * * *  p < 
0.001 vs. 4th quartile (highest NTproBNP group). 
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Table 3.  Patients divided into predialysis NTproBNP quartiles. Patients prescribed antihypertensive medications (BP meds) and patients 
prescribed 2 or more different antihypertensive agents (≥2 BP meds)
NTproBNP, pmol/l <123 123–283 283–989 >989
Age, years 57.1±16 61.7±16.7 65.3±14.1 64.6±16.2
Male, % 63.8 70.0 64.1 60.9
Caucasoid, % 31.9* 49.4 43.4 50.5
Diabetic, % 42.6 35.4 47.8 46.3
Vintage, months 22.2 (12–58) 27.3 (13–63) 28.7 (12–67) 43 (11–71)
BP meds, % 41.3* 45.8 56.4 61.3
≥2 BP meds 16.0* 16.7* 16.5* 32.3
MI, % 5.3* 4.2* 17.4 20.4
valve disease, % 3.3* 4.2* 8.7 17.2
Weight, kg 79.7±19.9* 75.6±20.6* 71.7±17.5 66.9±15.4
ICW, l 24.1±5.7 23.5±7.0 21.5±5.0 21.8±5.5
ECW, l 15.4±3.5 15.2±4.8 14.3±3.2 15.9±4.3
% body fat 31.8±12.0* 30.1±11.4 31.3±11.7 25.0±13.4
MAP pre, mm Hg 95.1±14.3* 92.0±14.1* 97.3±15.7 103.9±21.0
MAP post, mm Hg 88.7±14.9* 86.2±15.4* 91.4±14.3 95.8±21.4
Haemoglobin, g/l 117±13 112±14 113±14 112±17
Albumin, g/l 40.7±5.0 39.9±3.7 38.8±3.1 38.6±3.9
CRP, g/l 3 (1–8)* 5 (2–11)* 5 (2–10) 7 (3–16)
URR, % 73.7±8.7 76.0±6.5 74.8±8.7 73.4±8.6
 MI = Past medical history myocardial infarction; v = valvular heart disease; ICW = predialysis weight and bioimpedance volume as-
sessments, intracellular water; ECW = extracellular water; MAP = mean arterial blood pressure; CRP = C-reactive protein; URR = urea 
reduction ratio. Data expressed as mean ± standard deviation or median (interquartile range) or percentage. *  p < 0.05 vs. highest 
 NTproBNP quartile after correcting for multiple testing.
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 Fig. 2. Extracellular water (ECW) to total body water (TBW) ratio 
pre dialysis in patients divided into four quartiles according to 
predialysis NT-proBNP pmol/l. Data expressed as mean ± SD. 
 * *  p < 0.01 and  * * *  p < 0.001 vs. 4th quartile (highest NTproBNP 
group). 
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 Fig. 3. Relative extracellular water (ECW) overhydration accord-
ing to ESPEN guidelines pre dialysis, in patients divided into four 
quartiles according to predialysis NT-proBNP pmol/l. Data ex-
pressed as median, interquartile range and minimum to maxi-
mum.  *  p < 0.05, * *  p < 0.01 and  * * *  p < 0.001 vs. 4th quartile (high-
est NTproBNP group). 
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 Fluid overload in a haemodialysis patient is not simply 
present or absent, but rather a gradation. We therefore 
took a pragmatic approach to defining overhydration by 
using an ECW/TBW ratio of ≥0.415, which was 2 stan-
dard deviations from the postdialysis values and ≥2.0 litre 
ECW excess, as defined by the ESPEN  [18] . The relative 
area under ROC curves for predialysis NTproBNP for an 
ECW/TBW ratio of ≥0.415 and ECW excess of 2.0 were 
0.79 (95% confidence limits 0.72–0.85) and 0.73 (0.65–
0.8), respectively.
 Discussion
 Although previous reports of BNP measurements in 
dialysis patients have concurred that BNP is a strong 
prognostic marker for cardiac and all-cause mortality 
 [4] , there is debate as to whether BNP has any value in 
helping to determine volume status in dialysis patients 
 [10, 19] . In part, this is due to the lack of standardization 
of the different commercial and locally developed assays 
for natriuretic peptides, which are now available. Al-
though BNP and NT-proBNP are co-secreted in equimo-
lar amounts from the left and right cardiac ventricles in 
response to ventricular volume expansion and pressure 
overload, the larger NTproBNP, has a longer half-life, 
and is much more stable than BNP  [20, 21] . BNP values 
are more variable due to the shorter biological half-life of 
10–20 min, but also because BNP is less stable in vitro, 
especially if blood is not collected into plastic tubes con-
taining EDTA, or without other agents designed to pre-
vent degradation and also if analysis is delayed  [22, 23] . 
Predialysis BNP values vary with the dialysis week, being 
highest when patients are most volume overloaded prior 
to the first dialysis session of the week and lowest before 
the third dialysis session  [24] . In addition, while there is 
little or no clearance with low flux dialysis, some clear-
ance occurs with both high-flux dialysis and haemodi-
afiltration, although the difference postdialysis is least 
after the last dialysis session of the week  [24] . As such, we 
chose to standardise the results by making measure-
ments prior to the mid-week dialysis session. In keeping 
with previous reports, we found that NTproBNP was in-
creased in patients with a history of previous heart dis-
ease, including valvular heart disease, myocardial infarc-
tion, coronary artery bypass surgery and stenting and the 
number of antihypertensive drugs prescribed  [4, 9] . The 
general population-based Framington study, and other 
studies in haemodialysis patients  [11] have reported that 
overweight patients, and those with a greater body mass 
index had lower NTproBNP concentrations  [25] . Our re-
sults are in agreement with these findings, but while re-
ports in the general population have linked obesity to 
lower BNP values  [26] , we observed greater NTproBNP 
values in those with lower body fat. This may reflect dif-
ferences in body composition associated with chronic 
uraemia and dialysis compared to the healthy general 
population  [17, 27] .
 Although some reports have suggested that BNP does 
not reflect volume status  [10] , we found that NTproBNP 
was greater in those patients with higher systolic blood 
pressure both pre and postdialysis, and although there 
was a simple correlation between NTproBNP and systol-
ic blood pressure, the r value was only 0.303, and as such, 
systolic blood pressure accounted only for some 9% of the 
variance in NTproBNP in our study population. Accord-
ing to the bioimpedance studies, most of the ECW gain 
between dialysis sessions is in the legs and trunk. As ECW 
gain does not directly equate with plasma volume expan-
sion, there is a limited association with systolic blood 
pressure.
 We observed an increased ECW to TBW ratio both pre 
and postdialysis and NTproBNP, linking NTproBNP to 
volume overload. In addition, we also expressed ECW ex-
cess as relative overhydration as suggested by the ESPEN 
 [18] , and again patients with the highest NTproBNP con-
centrations had greater ECW over-hydration both pre 
and postdialysis. Although our results support several 
previous studies  [4, 7, 8, 12] , the ratio of ECW/TBW can 
be increased by both expansion of the ECW and reduc-
tion in TBW because of a loss of intracellular water  [8] . 
As such, this may link inflammation and malnutrition 
with volume overload  [8, 27–29 ] due to increased vascu-
lar permeability. To support this relationship, we ob-
served univariate associations for serum CRP and inverse 
correlations with serum albumin, haemoglobin and body 
cell mass. However, on multivariate analysis only CRP 
remained statistically significant.
 We also found that the quartile with the highest NT 
proBNP concentrations had lower postdialysis weights 
and although similar dialysis session urea reduction ra-
tios, received shorter dialysis session times. This may sug-
gest that smaller patients receive shorter dialysis session 
times  [30, 31] , and as such may fail to achieve their target 
weight as unable to tolerate fluid removal in a shorter pe-
riod  [32] . This would support data that patients of normal 
body mass index (BMI) and women are reported to have 
reduced survival on haemodialysis in the United States 
because they typically have shorter session times com-
pared to men and those with higher BMIs  [29, 33] .
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 Our results show that predialysis NTproBNP is in-
creased with extracellular volume overload in haemodi-
alysis patients and as such could potentially be used as a 
guide to aid clinical judgement in determining the target 
weight. There is some clearance of NTproBNP with 
high-flux haemodialysis and haemodiafiltration, but as 
NTproBNP is one of the larger BNP peptides, clearance 
is much lower than with other BNP peptides Previous 
studies have measured postdialysis NTproBNP; howev-
er, the area under the ROC curve was somewhat lower 
0.72, and the 95% confidence limit range was wider 
at  0.58–0.86  [11] . As such, predialysis estimations of 
 NTproBNP appear to have greater clinical relevance in 
helping to assess volume status in dialysis patients. Se-
rial estimations of BNP peptides  [19] are more likely to 
be helpful in monitoring changes in target weight than 
single-point measurements. Although multi-frequency 
bioelectrical impedance assessments are an accepted 
method for assessing volume status in dialysis patients, 
this technique cannot be used for all patients, particu-
larly those with implantable defibrillators and some car-
diac pace makers, and amputees. In addition, total body 
bioimpedance devices may provide inaccurate estima-
tions of hydration status in haemodialysis patients with 
unilateral limb swelling or superior vena cava obstruc-
tion  [33] . As such, there may be a role for measuring 
 natriuretic peptides. Although both pre and post 
 NTproBNP measurements appear to be of similar pre-
dictive value, it would be more useful to measure 
 NTproBNP prior to dialysis to aid clinical assessment of 
volume status, especially as point-of-care testing now al-
lows for bedside monitoring.
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